Mitoxantrone
产品说明书
 |
同义名 : | Mitozantrone; NSC 301739 |
| CAS号 : | 65271-80-9 | |
| 货号 : | A207951 | |
| 分子式 : | C22H28N4O6 | |
| 纯度 : | 98% | |
| 分子量 : | 444.48 | |
| MDL号 : | MFCD00242942 | |
| 存储条件： |
Pure form Keep in dark place, sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 60 mg/mL(134.99 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Mitoxantrone functions as a potent inhibitor of topoisomerase II and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. It induces apoptosis in B-CLL (B-chronic lymphocytic leukemia) cells and exhibits antitumor activity[1][2][3][4]. Mitoxantrone additionally demonstrates anti-orthopoxvirus activity, with EC50 values of 0.25 μM for cowpox and 0.8 μM for monkeypox, respectively[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01142466 | Multiple Sclerosis, Relapsing-... 展开 >>Remitting 收起 << | Phase 4 | Completed | - | - |
| NCT01142466 | - | Completed | - | - | |
| NCT01055483 | Acute Myeloid Leukemia | Phase 1 | Completed | - | France ... 展开 >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.25mL 0.45mL 0.22mL |
11.25mL 2.25mL 1.12mL |
22.50mL 4.50mL 2.25mL |
| 参考文献 |
|---|